Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.95 USD
+0.01 (1.06%)
Updated Apr 23, 2024 04:00 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Accelerate Diagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 13 | 46 | 64 | 68 | 108 |
Receivables | 3 | 2 | 2 | 2 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 5 | 5 | 9 | 8 |
Other Current Assets | 5 | 3 | 2 | 3 | 2 |
Total Current Assets | 24 | 56 | 73 | 82 | 122 |
Net Property & Equipment | 2 | 3 | 5 | 6 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 4 | 2 | 2 | 1 |
Total Assets | 31 | 65 | 83 | 93 | 134 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 56 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 4 | 4 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 67 | 7 | 7 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 0 | 0 | 0 |
Convertible Debt | 36 | 0 | 108 | 141 | 130 |
Long-Term Debt | 0 | 17 | 0 | 5 | 0 |
Non-Current Capital Leases | 0 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 51 | 87 | 118 | 156 | 142 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 695 | 630 | 581 | 475 | 452 |
Retained Earnings | -669 | -607 | -571 | -493 | -415 |
Other Equity | -1 | 0 | 0 | 0 | 0 |
Treasury Stock | 45 | 45 | 45 | 45 | 45 |
Total Shareholder's Equity | -20 | -22 | -35 | -63 | -7 |
Total Liabilities & Shareholder's Equity | 31 | 65 | 83 | 93 | 134 |
Total Common Equity | -20 | -22 | -35 | -63 | -7 |
Shares Outstanding | 14.50 | 9.90 | 6.10 | 5.90 | 5.40 |
Book Value Per Share | -1.37 | -2.25 | -5.75 | -10.65 | -1.37 |
Fiscal Year End for Accelerate Diagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 13 | 21 | 31 | 32 |
Receivables | NA | 3 | 3 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | NA | 0 |
Inventories | NA | 3 | 4 | 5 | 5 |
Other Current Assets | NA | 5 | 5 | 4 | 3 |
Total Current Assets | NA | 24 | 32 | 42 | 43 |
Net Property & Equipment | NA | 2 | 3 | 3 | 3 |
Investments & Advances | NA | 0 | 0 | NA | 0 |
Other Non-Current Assets | NA | 0 | 0 | NA | 0 |
Deferred Charges | NA | 0 | 0 | NA | 0 |
Intangibles | NA | 0 | 0 | NA | 0 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 31 | 39 | 50 | 51 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 1 | 1 | 57 |
Accounts Payable | NA | 5 | 5 | 4 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | NA | 0 |
Current Portion Capital Leases | NA | 1 | 0 | 1 | 1 |
Accrued Expenses | NA | 3 | 5 | 4 | 6 |
Income Taxes Payable | NA | 0 | 0 | NA | 0 |
Other Current Liabilities | NA | 2 | 26 | 43 | 0 |
Total Current Liabilities | NA | 12 | 38 | 54 | 68 |
Mortgages | NA | 0 | 0 | NA | 0 |
Deferred Taxes/Income | NA | 1 | 1 | NA | 0 |
Convertible Debt | NA | 36 | 33 | 32 | 0 |
Long-Term Debt | NA | 0 | 0 | NA | 17 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 1 |
Other Non-Current Liabilities | NA | 1 | 1 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | NA | 0 |
Total Liabilities | NA | 51 | 74 | 89 | 90 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | NA | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 695 | 666 | 664 | 631 |
Retained Earnings | NA | -669 | -656 | -657 | -624 |
Other Equity | NA | -1 | 0 | -1 | -1 |
Treasury Stock | NA | 45 | 45 | 45 | 45 |
Total Shareholder's Equity | NA | -20 | -35 | -39 | -39 |
Total Liabilities & Shareholder's Equity | NA | 31 | 39 | 50 | 51 |
Total Common Equity | 0 | -20 | -35 | 99,960 | -39 |
Shares Outstanding | 21.60 | 14.50 | 14.30 | 14.30 | 9.90 |
Book Value Per Share | 0.00 | -1.37 | -2.45 | 6,990.23 | -3.91 |